Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thrombolysis in acute massive lung embolism].

G A Marbet1

  • 1Gerinnungs- und Fibrinolyselaboratorium, Kantonsspital, Basel.

Schweizerische Medizinische Wochenschrift
|August 9, 1988
PubMed
Summary

Thrombolytic therapy offers faster pulmonary resistance reduction for pulmonary embolism than heparin alone. This benefit, especially in massive cases, outweighs bleeding risks when contraindications are managed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prosthetic heart valves and rare hypersensitivity to vitamin K antagonists resulting from factor IX mutation: how to manage anticoagulation?

Haemophilia : the official journal of the World Federation of Hemophilia·2009
Same author

Unexpected bleeding following eyelid tumor resection leading to the rare diagnosis of acquired haemophilia.

Klinische Monatsblatter fur Augenheilkunde·2008
Same author

Quantification of coagulation factors and inhibitors. Still a special task.

Hamostaseologie·2006
Same author

[Heparins].

Therapeutische Umschau. Revue therapeutique·2003
Same author

[Factor XIII in man: a review].

Hamostaseologie·2002
Same author

Influence of the genetic background on platelet function, microparticle and thrombin generation in the common laboratory mouse.

Platelets·2002

Area of Science:

  • Cardiology
  • Pulmonary Medicine
  • Pharmacology

Context:

  • Pulmonary embolism (PE) poses significant hemodynamic challenges.
  • Heparin is the standard anticoagulant therapy for PE.
  • Rapid reduction of pulmonary vascular resistance is crucial in massive PE.

Purpose:

  • To compare the efficacy of thrombolytic therapy versus heparin alone in reducing pulmonary resistance.
  • To evaluate the bleeding risk associated with thrombolytic therapy in PE.
  • To propose practical dosage regimens for streptokinase and urokinase in PE treatment.

Summary:

  • Thrombolytic agents significantly decrease total pulmonary resistance more rapidly than heparin monotherapy in patients with pulmonary embolism.
  • The hemodynamic advantages of thrombolysis in massive PE generally supersede the associated moderate increase in bleeding risk, provided contraindications are rigorously adhered to.
  • The study outlines practical dosing strategies for streptokinase and urokinase, facilitating clinical application.

Impact:

  • Provides evidence supporting the use of thrombolytic therapy for rapid hemodynamic improvement in pulmonary embolism.
  • Offers guidance on risk-benefit assessment for thrombolysis in massive PE.
  • Establishes practical dosage recommendations for key thrombolytic agents, aiding clinical decision-making.

Related Experiment Videos